UnitedHealthcare Denied Genetic Testing? How to Appeal

Genetic testing has become a cornerstone of modern precision medicine — from identifying hereditary cancer risk (BRCA1/BRCA2 pathogenic variants) to guiding medication selection through pharmacogenomics and diagnosing rare inherited conditions. Despite growing clinical evidence and guideline support, UnitedHealthcare (UHC) denies a significant volume of genetic testing claims, often citing lack of medical necessity or the patient's failure to meet specific Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization criteria. If UHC has denied your genetic test, this guide explains UHC's review process, why denials occur, and how to build an effective appeal.

Why UnitedHealthcare Denies Genetic Testing Claims

UHC applies detailed clinical coverage determination policies — published as Coverage Determination Guidelines (CDGs) — that set out specific eligibility criteria for each category of genetic testing. Denials typically arise from these predictable patterns:

• Patient does not meet UHC's personal or family history criteria: For hereditary cancer testing (BRCA1/BRCA2, Lynch syndrome, etc.), UHC requires specific personal or family history thresholds — such as a first-degree relative with breast cancer before age 50, or a known pathogenic variant in the family. Claims are denied when the clinical documentation submitted does not clearly establish that the patient meets these thresholds, even if the ordering physician believes the patient qualifies.
• Test ordered by a non-specialist: Some UHC policies require hereditary cancer genetic testing to be ordered by or in consultation with a board-certified genetic counselor or clinical geneticist. Claims ordered by a primary care physician without documented genetic counseling are more likely to be denied.
• Pharmacogenomic testing for medication management: UHC's coverage for pharmacogenomic testing (e.g., CYP2D6, CYP2C19 genotyping for psychiatry or pain management) is narrow. Many pharmacogenomic panels are denied as not meeting UHC's "clinical utility" requirement — the insurer requires evidence not just that the test can identify genetic variants, but that the results will directly change clinical management.
• Whole exome or genome sequencing denials: Comprehensive genomic sequencing is typically covered only for patients with complex, undiagnosed conditions that have not responded to standard diagnostic workup. Claims for whole exome sequencing without documented prior negative diagnostic workup are routinely denied.
• Test performed at an out-of-network laboratory: UHC may deny or significantly limit reimbursement when genetic testing is performed at a laboratory outside UHC's contracted network, even if the ordering provider is in-network.
• Duplicate testing within a lookback period: UHC policies typically deny genetic testing if a similar test has been performed within a defined lookback period (often 3–5 years), regardless of whether the clinical question being addressed has changed.

How to Appeal a UHC Genetic Testing Denial

Step 1: Identify the Specific UHC Coverage Determination Guideline That Was Applied

Request the specific UHC Coverage Determination Guideline (CDG) applied to your claim. UHC publishes these policies online at uhcprovider.com, but members can also request them in writing. Match the denial reason against the exact language of the CDG — sometimes UHC's reviewer misapplies the criteria or applies an outdated version of the policy.

Step 2: Verify That Your Clinical Documentation Meets UHC's Stated Criteria

Review the CDG's eligibility criteria against your medical record. If UHC requires documentation of a first-degree relative with ovarian cancer and that information is in the medical record but was not included in the prior authorization submission, the denial may be purely administrative and correctable with a resubmission. If the criteria are genuinely not met, the appeal must argue either for a medical exception or challenge the criteria as inconsistent with clinical guidelines.

Step 3: Obtain Documentation From a Genetic Counselor

For hereditary cancer testing and other complex genetic assessments, a letter from a board-certified genetic counselor documenting the patient's personal and family history, the specific genes being tested, the clinical rationale, and the applicable clinical guidelines (NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic; or Colorectal for Lynch syndrome) significantly strengthens the appeal. NCCN guidelines are the most widely recognized standard for hereditary cancer genetic testing — if the patient meets NCCN Category 1 or 2A criteria, document this explicitly.

Step 4: Argue Clinical Utility for Pharmacogenomic or Novel Test Denials

If UHC denied the test for lack of clinical utility, the appeal must demonstrate that test results will directly influence clinical management. Cite peer-reviewed evidence — published clinical trials or professional society guidelines — showing that patients with the patient's profile benefit from testing. For pharmacogenomic denials, cite relevant FDA drug labeling with pharmacogenomic information (the FDA publishes a Table of Pharmacogenomic Biomarkers in Drug Labeling) as evidence that the genetic information is directly actionable.

Step 5: Submit the Internal Appeal Within UHC's Deadline

UHC requires internal appeals to be submitted within 180 days of the adverse benefit determination for most health plan members. Submit the appeal in writing to UHC's appeals department, addressed to the Member Appeals unit. Include the denial letter, the genetic counselor's letter, the relevant clinical records, applicable NCCN or other guideline documentation, and a cover letter explicitly addressing each reason cited in the denial. Request a peer-to-peer review between the ordering physician and UHC's medical director.

Step 6: Request External Independent Review: Complete Guide" class="auto-link">External Review If the Internal Appeal Fails

If UHC upholds the denial internally, request an independent external review. External reviewers are not bound by UHC's CDGs and instead apply broadly recognized medical standards. For genetic testing denials where NCCN guidelines or major professional society recommendations clearly support the test, external reviews frequently result in reversal. Additionally, UHC members are protected by GINA (Genetic Information Nondiscrimination Act) — UHC cannot use genetic test results to deny coverage or increase premiums, though GINA does not mandate coverage of the testing itself.

What to Include in Your UHC Genetic Testing Appeal

• UHC Coverage Determination Guideline (CDG) that was applied, obtained from UHC or uhcprovider.com, alongside your medical record demonstrating how the criteria are met
• Letter from a board-certified genetic counselor documenting personal and family history, clinical rationale, and NCCN guideline basis for the recommended test
• NCCN Guidelines (Genetic/Familial High-Risk Assessment) confirming the patient meets testing criteria, with the applicable category highlighted
• Peer-reviewed literature or FDA pharmacogenomic biomarker labeling supporting clinical utility (for pharmacogenomic test denials)
• Denial letter, EOB)" class="auto-link">Explanation of Benefits, and any prior authorization denial documentation

Fight Back With ClaimBack

UHC genetic testing denials are highly technical — but when NCCN guidelines or other major clinical standards clearly support the test, the clinical argument for coverage is strong. ClaimBack generates a professional appeal citing UHC's specific CDGs, NCCN criteria, and your clinical documentation in 3 minutes. Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal